European journal of clinical pharmacology · 2026
Pharmacological interventions targeting cognition and related clinical outcomes in vascular dementia: a systematic review and meta-analysis of randomized controlled trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Tianyu, Zhang Lin, Zhang Yizhou, Liang Huazheng, Wang Junyan, Chen Gengzhen, Huo Yujia
Аннотация
PURPOSE: Randomized evidence for pharmacological interventions in vascular dementia (VaD) is fragmented. We conducted a VaD-focused, scale-specific systematic review and meta-analysis.
METHODS: We searched four databases for English-language parallel-group randomized controlled trials (1990-2025). Comparable placebo-controlled outcomes were pooled using random-effects meta-analysis; non-poolable outcomes were synthesized according to SWiM. Risk of bias and certainty were assessed with RoB 2 and GRADE.
RESULTS: Sixteen trials included 5,668 participants across trial cohorts; with one exception, all were published in 2012 or earlier. EGb 761® was evaluated in three trials; nimodipine, galantamine, memantine, and rivastigmine in two each; and pentoxifylline, citicoline, sulodexide, donepezil, and Tianzhi granule in one each. Galantamine reduced ADAS-Cog/11 scores (2 trials, n = 1,332; MD - 2.01, 95% CI - 3.18 to - 0.85) and ADAS-Cog/13 scores (2 trials, n = 1,328; MD - 2.51, 95% CI - 3.87 to - 1.15), and memantine reduced ADAS-Cog/11 scores (2 trials, n = 752; MD - 2.20, 95% CI - 3.24 to - 1.15); certainty was moderate. EGb 761® reduced SKT scores (3 trials, n = 283; MD - 2.65, 95% CI - 5.17 to - 0.12), but heterogeneity was extreme (I²=92.8%; very low certainty). Galantamine showed no clear NPI benefit (2 trials, n = 1,310; MD - 0.13, 95% CI - 4.05 to 3.79), and memantine showed no clear GBS benefit (2 trials, n = 595; MD - 1.93, 95% CI - 4.69 to 0.84). Evidence for the other seven interventions was mainly single-trial and non-poolable; functional and global outcomes did not establish consistent benefit.
CONCLUSION: Galantamine and memantine showed small short-term cognitive effects; EGb 761® suggested a fragile, very low-certainty signal; patient-important benefits remain uncertain.
METHODS: We searched four databases for English-language parallel-group randomized controlled trials (1990-2025). Comparable placebo-controlled outcomes were pooled using random-effects meta-analysis; non-poolable outcomes were synthesized according to SWiM. Risk of bias and certainty were assessed with RoB 2 and GRADE.
RESULTS: Sixteen trials included 5,668 participants across trial cohorts; with one exception, all were published in 2012 or earlier. EGb 761® was evaluated in three trials; nimodipine, galantamine, memantine, and rivastigmine in two each; and pentoxifylline, citicoline, sulodexide, donepezil, and Tianzhi granule in one each. Galantamine reduced ADAS-Cog/11 scores (2 trials, n = 1,332; MD - 2.01, 95% CI - 3.18 to - 0.85) and ADAS-Cog/13 scores (2 trials, n = 1,328; MD - 2.51, 95% CI - 3.87 to - 1.15), and memantine reduced ADAS-Cog/11 scores (2 trials, n = 752; MD - 2.20, 95% CI - 3.24 to - 1.15); certainty was moderate. EGb 761® reduced SKT scores (3 trials, n = 283; MD - 2.65, 95% CI - 5.17 to - 0.12), but heterogeneity was extreme (I²=92.8%; very low certainty). Galantamine showed no clear NPI benefit (2 trials, n = 1,310; MD - 0.13, 95% CI - 4.05 to 3.79), and memantine showed no clear GBS benefit (2 trials, n = 595; MD - 1.93, 95% CI - 4.69 to 0.84). Evidence for the other seven interventions was mainly single-trial and non-poolable; functional and global outcomes did not establish consistent benefit.
CONCLUSION: Galantamine and memantine showed small short-term cognitive effects; EGb 761® suggested a fragile, very low-certainty signal; patient-important benefits remain uncertain.